Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.

Lamarca, Angela; Barriuso, Jorge; McNamara, Mairéad G; Hubner, Richard A; Manoharan, Prakash; Mansoor, Wasat; Valle, Juan W

Lamarca, Angela; Barriuso, Jorge; McNamara, Mairéad G; Hubner, Richard A; Manoharan, Prakash; Mansoor, Wasat; Valle, Juan W.

Afiliación

Lamarca A; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom, angela.lamarca@christie.nhs.uk.
Barriuso J; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom, angela.lamarca@christie.nhs.uk.
McNamara MG; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Hubner RA; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Manoharan P; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Mansoor W; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Valle JW; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Neuroendocrinology ; 110(1-2): 155-157, 2020.

Article en En | MEDLINE | ID: mdl-31527383

Asunto(s)

Tumores Neuroendocrinos; Temozolomida; Capecitabina; Duración de la Terapia; Fluorouracilo; Humanos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumores Neuroendocrinos / Temozolomida Límite: Humans Idioma: En Revista: Neuroendocrinology Año: 2020 Tipo del documento: Article Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google